Amarin Corp plc (AMRN) Affirms Commitment to Completion of REDUCE-IT

September 16, 2014 10:39 AM

5 0

Amarin Corp plc (Nasdaq: AMRN) announced its continued commitment to completing the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) cardiovascular outcomes study. This multinational, prospective, randomized, double-blind, placebo-controlled study is the first prospective cardiovascular outcomes study of any drug in a population of patients who, despite stable statin therapy, have elevated triglyceride levels.

The REDUCE-IT study is being conducted with Vascepa® (icosapent ethyl) capsules, a highly-pure EPA omega-3 prescription product. Vascepa is currently approved as an adjunct to diet to reduce triglyceride levels in adult patients with severely high (>500 mg/dL) triglyceride levels, based on results f...

Read more

To category page